Guardant Health (GH) closed at $150.87 on November 6, 2026, down 1.7% from the previous close, on volume of 5,038,754 shares (30-day average 1,773,597).
Data as of November 6, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 8, 2026 | Put Spread | 20-Nov-26130 : 160 P | 3,320 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Guardant Health (GH) Gets a Buy from Bank of America Securities
TipRanks (Sat, 7-Nov 12:36 AM ET)
Stifel Nicolaus Remains a Buy on Guardant Health (GH)
TipRanks (Fri, 6-Nov 2:39 PM ET)
Goldman Sachs Reaffirms Their Buy Rating on Guardant Health (GH)
TipRanks (Fri, 6-Nov 9:58 AM ET)
Guardant Health (GH) Receives a Buy from Canaccord Genuity
TipRanks (Fri, 6-Nov 9:53 AM ET)
Guardant Health (GH) Gets a Buy from Piper Sandler
TipRanks (Fri, 6-Nov 9:37 AM ET)
At a glance: stocks gapping down premarket
Seeking Alpha News (Fri, 6-Nov 6:54 AM ET)
Guardant Health (GH) Receives a Buy from Barclays
TipRanks (Fri, 6-Nov 4:08 AM ET)
Guardant Health Non-GAAP EPS of -$0.29 beats by $0.02, revenue of $361M beats by $10.36M
Seeking Alpha News (Thu, 5-Nov 4:22 PM ET)
Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Business Wire (Thu, 5-Nov 4:05 PM ET)
Business Wire (Thu, 5-Nov 7:30 AM ET)
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Guardant Health trades on the NASDAQ stock market under the symbol GH.
As of November 9, 2026, GH stock price climbed to $159.21 with 2,265,174 million shares trading.
GH has a beta of 0.54, meaning it tends to be less sensitive to market movements. GH has a correlation of 0.01 to the broad based SPY ETF.
GH has a market cap of $21.37 billion. This is considered a Large Cap stock.
Last quarter Guardant Health reported $361 million in Revenue and -$.29 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.10.
In the last 3 years, GH traded as high as $191.05 and as low as $15.81.
The top ETF exchange traded funds that GH belongs to (by Net Assets): VTI, VB, VBK, VXF, IWP.
GH has outperformed the market in the last year with a return of +65.4%, while the SPY ETF gained +13.7%. In the last 3 month period, GH beat the market returning +1.0%, while SPY returned -1.6%. However, in the most recent 2 weeks GH has underperformed the stock market by returning -5.8%, while SPY returned -0.7%.
GH support price is $146.39 and resistance is $155.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GH shares will trade within this expected range on the day.
